Skip to content
On Friday Mar. 21, Keith Krehbiel went from being the first human subject at the Stanford site of the international ADAPT-PD clinical study to becoming the first person in the U.S. to receive adaptive Deep Brain Stimulation (aDBS), a newly FDA-approved treatment for symptoms of Parkinson’s disease, as a part of his regular medical care. (Dai Sugano/Bay Area News Group)
On Friday Mar. 21, Keith Krehbiel went from being the first human subject at the Stanford site of the international ADAPT-PD clinical study to becoming the first person in the U.S. to receive adaptive Deep Brain Stimulation (aDBS), a newly FDA-approved treatment for symptoms of Parkinson’s disease, as a part of his regular medical care. (Dai Sugano/Bay Area News Group)
Author
UPDATED:

Adaptive Deep Brain Stimulation isn't a cure — but it's a total game changer.

Subscribe to continue reading this article.

Already subscribed? To log in, click here.

Originally Published:

RevContent Feed